Actinium Pharmaceuticals
Update in progressATNM (NYSE American)
- Company RatingNeutralCompany RatingCombines sentiment and sustainability signals into an overall assessment of the company.Great · Good · Neutral · At Risk · Poor
- SectorHealthcare
- IndustryBiotechnology
Actinium Pharmaceuticals develops antibody–radiation conjugates and targeted radiotherapies to improve outcomes after failed cancer treatments. Lead assets include Actimab-A (CD33 radiotherapeutic for Relapsed/Refractory AML, in Phase 2/3), Iomab-ACT to enable cellular therapies like CAR-T, ATNM-400 (alpha emitter for prostate cancer), and Iomab-B for conditioning before bone marrow transplant. Also collaborates with the NCI on Actimab-A and pursues preclinical programs for solid tumors. Based in New York.
Company score
- Sentiment
- 0.36
- SentimentMeasures the overall tone of recent coverage and discussion about the company.−10 negative · 0 neutral · +10 positive
- Environment
- 0.00
- EnvironmentAssesses the company’s environmental impact, risks, and sustainability practices.−10 negative · 0 neutral · +10 positive
- Social
- 0.08
- Governance
- 0.00
- GovernanceAssesses leadership, accountability, transparency, and business ethics.−10 negative · 0 neutral · +10 positive
- Sustainability
- 0.02
- SustainabilityCombines environmental, social, and governance signals into an overall sustainability score.−10 negative · 0 neutral · +10 positive
- Impact Score
- 0.19
- Impact ScoreCombines sentiment and sustainability performance into an assessment of the company’s overall impact.−10 negative · 0 neutral · +10 positive
Sort by
Order by
Timeframe
No news articles are available for this company yet.
Unable to load company news.
Loading more news
You're all caught up!